Medtronic, St. Jude Will Not Take CRT Market Share, Guidant Vows
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects to maintain its 38% share of the cardiac resynchronization therapy (CRT) market in the second half of 2004 despite a recent Medtronic launch and emerging competition from St. Jude